More on Sangamo BioSciences' (SGMO) Q2: Collaboration agreements with Shire and Sigma-Aldrich...

|About: Sangamo Therapeutics, Inc. (SGMO)|By:, SA News Editor

More on Sangamo BioSciences' (SGMO) Q2: Collaboration agreements with Shire and Sigma-Aldrich account for $6.2M of the $6.9M in revenue the company recognized during the period with the balance consisting of research grants. SGMO's collaboration with Shire brings in $4.7M during the quarter. R&D expenses rise 22% Y/Y on "increased external expenses related to … preclinical programs." FY13 guidance: Revenue of $20-24M, $46-50M in operating expenses, and cash and cash equivalents of "at least" $55M by the end of the year. Shares +1.19% AH. (PR)